Hot Products

Ginkgolide A
Catalog No: CFN99638

Ginkgolide A is a platelet-activating factor antagonist, it can inhibit the neurotoxicity of prions or amyloid-beta1-42, may be relevant treatments for prion or Alzheimer's diseases.Ginkgolide A has neuroprotective, and anxiolytic-like effects, it is widely used for the treatment of cardiovascular diseases and diabetic vascular complications, which might be achieved through regulating the STAT3-mediated pathway.

Ginkgolide B
Catalog No: CFN99640

Ginkgolide B has potent neuroprotective, anti-arrhythmias, anti-inflammatory and anti-apoptotic effects, it might be a promising drug on inhibiting platelet function and reducing inflammation in atherosclerosis.Ginkgolide B retards the proliferation and development of mouse embryonic stem cells (ESCs) and blastocysts in vitro and causes developmental injury in vivo.

Ginkgolide C
Catalog No: CFN99639

Ginkgolide C is a potent inhibitor of collagen-stimulated platelet aggregation, it may increase intracellular cAMP and cGMP production and MMP-9 activity, inhibit intracellular Ca(2+) mobilization and TXA(2) production. Ginkgolide C has anti-adipogenic and ameliorating Alzheimer disease effects; it also can increase△LVP significantly,enhances the myocardial systolic and diastolic function of rats,but has no significant effect on HR while it shows inotropic activity.

Ginkgolide J
Catalog No: CFN99149

Ginkgolide J has neuroprotective activity, it can prevent A beta(1-42) induced inhibition of long-term potentiation in the CA1 region of mouse hippocampal slices, it is also capable of inhibiting cell death of rodent hippocampal neurons caused by A beta(1-42). Ginkgolide J can inhibit platelet aggregation induced by ADP or PAF.

Ginkgolide K
Catalog No: CFN91009

Ginkgolide K exerts anti-oxidative stress and neuroprotective effect on ischemic stroke, it has potentially anti- Parkinson's disease activity, it can promote the clearance of A53T mutation alpha-synuclein in SH-SY5Y cells. Ginkgolide K promotes angiogenesis after ischemia stroke through increasing the expression of HIF-1α/VEGF via JAK2/STAT3 pathway, it promotes astrocyte proliferation and migration after oxygen-glucose deprivation via inducing protective autophagy through the AMPK/mTOR/ULK1 signaling pathway. Ginkgolide K can inhibit PAF-induced platelet aggregation and improve nerve injury after cerebral ischemia-reperfusion.

Ginsenoside Compound K
Catalog No: CFN99756

Ginsenoside compound K (C-K) is a metabolite of the protopanaxadiol-type saponins of Panax ginseng C.A. Meyer, has long been used to treat against the development of cancer, inflammation, allergies, and diabetes; C-K acts as a unique HUVEC migration inhibitor by regulating MMP expression, as well as the activity of SPHK1 and its related sphingolipid metabolites. C-K exhibits anti-inflammatory effects by reducing iNOS and COX-2, C-K exhibits an inhibition against the activity of CYP2C9 and CYP2A6 in human liver microsomes with IC50s of 32.0±3.6 μM and 63.6±4.2 μM, respectively. C-K promotes Aβ clearance by enhancing autophagy via the mTOR signaling pathway in primary astrocytes.

Ginsenoside F1
Catalog No: CFN99754

Ginsenoside has been reported to suppress platelet aggregation and to reduce gap junction-mediated intercellular communication, also as a novel anti-skin cancer drug with anti-proliferative and anti-migration features. Ginsenoside F1 has a potential for industrial cosmetic materials, it also has inhibitory effect of elastase and tyrosinase, it significantly reduces ultraviolet-B-induced cell death by maintaining constant levels of Bcl-2 and protects HaCaT cells from apoptosis caused by ultraviolet B irradiation.

Ginsenoside F2
Catalog No: CFN99755

Ginsenoside F2, an autophagic initiater, which has anti-cancer, and anti-obesity activities. Ginsenoside F2 inhibited the growth and invasion of cancer, and activated the intrinsic apoptotic pathway and mitochondrial dysfunction. Ginsenoside F2 suppresses hair cell apoptosis and premature entry to catagen more effectively than finasteride, it decreases the expression of TGF-β2 and SCAP proteins, the factors in the SCAP pathway could be targets for hair loss prevention drugs.

Ginsenoside F3
Catalog No: CFN99978

Ginsenoside F3 has immunoenhancing activity by regulating production and gene expression of type 1,type 2 cytokines in murine spleen cells. It enhances the NF-kappaB DNA binding activity induced by ConA in murine spleen cells with 10 micromol/L.

Ginsenoside F4
Catalog No: CFN90757

Ginsenoside F4 has inhibitory effect on human lymphocytoma JK cell by inducing its apoptosis, the mechanism is related to the mitochondrial dysfunction and the increase of Bax expression and decrease of Bcl-2 expression. Ginsenoside F4 also has strongly inhibit activation of p38 mitogen-activated protein kinase in signal transduction pathways.